Stocks · News reference
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has entered into a
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-09-04 AccNo: 0001193125-26-383645 Size: 236 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarIntellia Therapeutics announced a $400 million non-dilutive senior secured term loan facility with OrbiMed, consisting of $75 million upfront and $325 million tied to milestones. The financing provides strategic flexibility as the company advances toward U.S. approval and commercial launch of lonvo-z for hereditary angioedema treatment, while also supporting advancement of nexiguran ziclumeran in transthyretin amyloidosis.
Read original at globenewswire-incIntellia Therapeutics reported positive Phase 3 HAELO clinical data for lonvo-z in HAE, with results presented at EAACI and published in the New England Journal of Medicine. The company anticipates FDA acceptance of a BLA (Biologics License Application) for lonvo-z in the second half of 2026.
Read original at globenewswire-inc